Chemotherapy Companies

Top Industry Leaders in the Chemotherapy Market

*Disclaimer: List of key companies in no particular orderLatest Chemotherapy Companies Update

Oct 2023: Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are less than expected and cut revenue expectations for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. The company said that global usage of Paxlovid is trending slightly above last year but still below expectations. The fall vaccination period just began, and the New York City drugmaker said it is too soon to get a handle on year-round vaccination rates. That number also accounts for delayed product commercialization, pushed to January 2024 from the company’s previous expectation of commercialization in the second half of this year.

June 2023: The US Food and Drug Administration has acknowledged and granted Priority Review to AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) used together with chemotherapy for the medical management of adult patients with advanced locally or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). Applications for drugs that, if approved, would provide significant enhancements over current choices by demonstrating safety or efficacy enhancements, preventing serious illnesses, or improving patient compliance are given Priority Review by the Food and Drug Administration (FDA). Importantly, individuals with central nervous system metastases were included in the subgroups that showed a clinically significant PFS advantage.

List of Chemotherapy Key companies in the market